Close

Merck to acquire Themis for SARS-CoV-2 vaccine

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The Ultimate Pain Relief Guide: Proven Tips to Manage Discomfort Naturally

Pain is something that we all go through somehow...

Merck announced on May 26 that it has entered an agreement to acquire privately held Themis, a company that is developing a vaccine candidate for SARS-CoV-2.

Themis has a pipeline of vaccine candidates and immune modulatory therapies developed using its measles virus vector platform. Originally developed by scientists at the Institut Pasteur, the technology was exclusively licensed to Themis in 2010.

In response to COVID-19, Themis formed a consortium to develop a SARS-CoV-2 vaccine in collaboration with Institut Pasteur and the Center for Vaccine Research at the University of Pittsburgh. Funding has been provided by the Coalition for Epidemic Preparedness Innovations (CEPI).

The acquisition is expected to advance the development of Themis’ vaccine candidate, which is currently in preclinical development, and scheduled for clinical trials later in 2020. Under the agreement, Merck will acquire all outstanding shares of Themis in exchange for an undisclosed cash payment. Upon completion of the deal Themis will become a wholly owned subsidiary of Merck.

Institut Pasteur, CEPI, and Merck have entered into a memorandum of understanding whereby the organizations agree to address the COVID-19 pandemic by developing, manufacturing, and distributing the vaccine on a global basis and with pricing that makes the vaccine both available around the world and accessible to those who need it.

Latest stories